Pompe disease: Unmet needs and emerging therapies

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Pompe disease results from reduced acid alpha-glucosidase activity, leading to glycogen buildup.
• Current enzyme replacement therapies (ERTs) like alglucosidase alfa have limitations, with some patients showing suboptimal responses or decline.
• New ERTs (avalglucosidase alfa, cipaglucosidase alfa/miglustat) offer advancements, but unmet needs persist, including central nervous system involvement.

Purpose of the Study:

• To review challenges with existing Pompe disease treatments.
• To summarize emerging therapies in preclinical and clinical development.
• To highlight novel therapeutic strategies for Pompe disease and related lysosomal storage disorders.

Main Methods:

• Literature review of current and emerging Pompe disease therapies.
• Analysis of treatment mechanisms, including ERT, substrate reduction, and gene therapy.
• Discussion of challenges and potential of novel therapeutic approaches.

Main Results:

• Existing ERTs provide benefits but have limitations in efficacy and patient response.
• New ERTs represent advancements but may not fully address all patient needs.
• Emerging therapies show promise in targeting specific tissues, reducing substrate, or restoring enzyme production.

Conclusions:

• Innovative treatments are needed to overcome limitations of current Pompe disease therapies.
• Tissue-targeted ERT, substrate reduction therapy, and gene therapy offer promising future options.
• These novel approaches aim to more effectively treat glycogen accumulation and improve patient quality of life.